סלובניה -
סלובנית -
JAZMP (Javna agencija RS za zdravila in medicinske pripomočke)
anesia 10 mg/ml emulzija za injiciranje ali infundiranje
uab norameda - propofol - emulzija za injiciranje/infundiranje - propofol 10 mg / 1 ml - propofol
האיחוד האירופי -
סלובנית -
EMA (European Medicines Agency)
draxxin
zoetis belgium sa - tulatromicin - antibakterij za sistemsko uporabo - pigs; cattle; sheep - govedo: zdravljenje in metaphylaxis goved, bolezni dihal (brd), ki je povezana z mannheimia haemolytica, pasteurella multocida, histophilus somni in mikroplazma bovis občutljivi na tulathromycin. prisotnost bolezni v čredi je treba določiti pred metafilaktičnim zdravljenjem. zdravljenje nalezljivih goveja keratoconjunctivitis (ibk), ki je povezana z moraxella bovis občutljivi na tulathromycin. prašiči: zdravljenje in metaphylaxis prašičje bolezni dihal (srd), ki je povezana z actinobacillus pleuropneumoniae, pasteurella multocida, mikroplazma hyopneumoniae, haemophilus parasuis in bordetella bronchiseptica, občutljivo za tulathromycin. prisotnost bolezni v čredi je treba določiti pred metafilaktičnim zdravljenjem. zdravilo draxxin je dovoljeno uporabljati samo, če se prašiči pričakujejo, da bodo bolezen razvili v 2-3 dneh. ovce: zdravljenje zgodnjih fazah nalezljivih pododermatitis (stopala gnilobe), ki je povezana s sovražno dichelobacter nodosus, ki zahteva sistemsko zdravljenje.
האיחוד האירופי -
סלובנית -
EMA (European Medicines Agency)
purevax rc
boehringer ingelheim vetmedica gmbh - attenuated feline rhinotracheitis herpesvirus (fhv f2 strain), inactivated feline calicivirosis antigens (fcv 431 and g1 strains) - immunologicals za skupin felidae, - mačke - active immunisation of cats aged eight weeks and older:against feline viral rhinotracheitis to reduce clinical signs;against calicivirus infection to reduce clinical signs. onsets of immunity isone week after primary vaccination course. the duration of immunity is one year after primary vaccination course and three years after the last re-vaccination.
האיחוד האירופי -
סלובנית -
EMA (European Medicines Agency)
purevax rcch
merial - attenuated feline rhinotracheitis herpesvirus (fhv f2 strain), inactivated feline calicivirosis antigens (fcv 431 and g1 strains), attenuated chlamydophila felis (905 strain) - immunologicals za skupin felidae, - mačke - active immunisation of cats aged 8 weeks and older:against feline viral rhinotracheitis to reduce clinical signs;against calicivirus infection to reduce clinical signs and excretion;against chlamydophila felis infection to reduce clinical signs. na imunski sistem je bil dokazan 1 teden po osnovnem cepljenju za rinotraheitis, kalicivirus in komponento chlamydophila felis. trajanje imunosti je 1 leto po zadnjem (ponovnem) cepljenju.
האיחוד האירופי -
סלובנית -
EMA (European Medicines Agency)
purevax rcp
boehringer ingelheim vetmedica gmbh - attenuated feline panleucopenia virus (pli iv) - immunologicals za skupin felidae, - mačke - active immunisation of cats aged eight weeks and older:against feline viral rhinotracheitis to reduce clinical signs;against calicivirus infection to reduce clinical signs;against feline panleucopenia to prevent mortality and clinical signs. onset of immunity is one week after primary vaccination course the duration of immunity is one year after the primary vaccination course and three years after the last re-vaccination.
האיחוד האירופי -
סלובנית -
EMA (European Medicines Agency)
purevax rcpch
boehringer ingelheim vetmedica gmbh - attenuated feline rhinotracheitis herpesvirus (fhv f2 strain), inactivated feline calicivirosis antigens (fcv 431 and g1 strains), attenuated chlamydophila felis (905 strain), attenuated feline panleucopenia virus (pli iv) - immunologicals za skupin felidae, - mačke - active immunisation of cats aged eight weeks and older:• against feline viral rhinotracheitis to reduce clinical signs;• against calicivirus infection to reduce clinical signs;• against chlamydophila felis infection to reduce clinical signs;• against feline panleucopenia to prevent mortality and clinical signs. nastopi imunosti so dokazali en teden po primarno cepljenje seveda za rhinotracheitis, calicivirus, chlamydophila felis in panleucopenia komponente. the duration of immunity is one year after the last re-vaccination for the chlamydiosis component, and oneyear after primary vaccination and three years after the last re-vaccination for the rhinotracheitis, calicivirosis and panleucopenia components.
האיחוד האירופי -
סלובנית -
EMA (European Medicines Agency)
shingrix
glaxosmithkline biologicals sa - recombinant varicella zoster virus glycoprotein e - herpes zoster - cepiva - shingrix is indicated for prevention of herpes zoster (hz) and post-herpetic neuralgia (phn), in:adults 50 years of age or older;adults 18 years of age or older at increased risk of hz. uporaba shingrix mora biti v skladu z uradnimi priporočili.
סלובניה -
סלובנית -
JAZMP (Javna agencija RS za zdravila in medicinske pripomočke)
propodine
dechra regulatory -